Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases

被引：0
作者：
Nejabat, Mojgan [1 ]
Hadizadeh, Farzin [2 ]
Almahmeed, Wael [3 ]
Sahebkar, Amirhossein [4 ,5 ]
机构：
[1] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Iran
[2] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran
[3] Cleveland Clin Abu Dhabi, Heart & Vasc Inst, Abu Dhabi, U Arab Emirates
[4] Saveetha Univ, Saveetha Med Coll & Hosp, Saveetha Inst Med & Tech Sci, Ctr Global Hlth Res, Chennai, India
[5] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran
来源：
DRUG DISCOVERY TODAY | 2025年 / 30卷 / 03期
关键词：
proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i); diabetes; cancer; cardiovascular; cerebrovascular; stroke; LDL-CHOLESTEROL; METAANALYSIS; PREVENTION; EFFICACY; THERAPY; PEOPLE; SAFETY; RISK; ERA;
D O I：
10.1016/j.drudis.2025.104316
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have potential applications in cancer therapy and as cholesterol-lowering treatments. The impact of PCSK9 suppression on both tumor growth and metastasis, as well as the management of diabetes, has been demonstrated. PCSK9i can also enhance outcomes and reduce cardiovascular (CV) events in individuals with a history of such events. In this review, we provide insights into the pharmacology, safety, and impact of PCSK9i. We highlight cutting-edge investigations, the development of innovative PCSK9i-based products, and a more comprehensive understanding of the potential effects of these drugs on cancer, diabetes, and CV and cerebrovascular diseases.
引用
收藏
页数：15
相关论文
共 103 条
  • [1] Naturally Occurring PCSK9 Inhibitors
    Adorni, Maria Pia
    Zimetti, Francesca
    Lupo, Maria Giovanna
    Ruscica, Massimiliano
    Ferri, Nicola
    [J]. NUTRIENTS, 2020, 12 (05)
  • [2] Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis
    Alannan, Malak
    Fatrouni, Hala
    Trezeguet, Veronique
    Dittrich-Domergue, Franziska
    Moreau, Patrick
    Siegfried, Geraldine
    Liet, Benjamin
    Khatib, Abdel-Majid
    Grosset, Christophe F.
    Badran, Bassam
    Fayyad-Kazan, Hussein
    Merched, Aksam J.
    [J]. CELLS, 2023, 12 (01)
  • [3] Rewiring Lipid Metabolism by Targeting PCSK9 and HMGCR to Treat Liver Cancer
    Alannan, Malak
    Trezeguet, Veronique
    Amoedo, Nivea Dias
    Rossignol, Rodrigue
    Mahfouf, Walid
    Rezvani, Hamid Reza
    Dittrich-Domergue, Franziska
    Moreau, Patrick
    Lacomme, Sabrina
    Gontier, Etienne
    Grosset, Christophe F.
    Badran, Bassam
    Fayyad-Kazan, Hussein
    Merched, Aksam J.
    [J]. CANCERS, 2023, 15 (01)
  • [4] Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
    Albosta, Michael S.
    Grant, Jelani K.
    Taub, Pam
    Blumenthal, Roger S.
    Martin, Seth S.
    Michos, Erin
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2023, 19 : 421 - 431
  • [5] Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
    Almeida, Catarina R.
    Ferreira, Beatriz H.
    Duarte, Iola F.
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [6] The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
    Alshahrani, Awad
    Kholaif, Naji
    Al-Khnifsawi, Mutaz
    Zarif, Hawazen
    Mahzari, Moeber
    [J]. ADVANCES IN THERAPY, 2024, 41 (02) : 837 - 846
  • [7] Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
    Bandyopadhyay, Dhrubajyoti
    Ashish, Kumar
    Hajra, Adrija
    Qureshi, Arshna
    Ghosh, Raktim K.
    [J]. JOURNAL OF LIPIDS, 2018, 2018
  • [8] The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors
    Blanchard, Valentin
    Chemello, Kevin
    Hollstein, Tim
    Chong-Hong-Fong, Clement
    Schumann, Friederike
    Grenkowitz, Thomas
    Nativel, Brice
    Coassin, Stefan
    Croyal, Mikael
    Kassner, Ursula
    Lamina, Claudia
    Steinhagen-Thiessen, Elisabeth
    Lambert, Gilles
    [J]. CARDIOVASCULAR RESEARCH, 2022, 118 (09) : 2103 - 2111
  • [9] Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
    Cao, Ye-Xuan
    Liu, Hui-Hui
    Dong, Qiu-Ting
    Li, Sha
    Li, Jian-Jun
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (06) : 1391 - 1398
  • [10] Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?
    Cesaro, Arturo
    Acerbo, Vincenzo
    Raucci, Giuseppe
    Calabro, Paolo
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : I34 - I37
12345678910